Key result
High plasma levels of soluble CD40 ligand significantly increased the risk of vascular events in patients with nonvalvular atrial fibrillation (HR 4.63; 95% CI 1.92-11.20; P<0.001).
Why the study?
Does elevated soluble CD40 ligand predict stroke or myocardial infarction in patients with nonvalvular atrial fibrillation?
Population
231 patients with nonvalvular atrial fibrillation (177 [77%] permanent or persistent, 54 [23%] paroxysmal)
Comparison
High levels of soluble CD40 ligand vs Low levels of soluble CD40 ligand
Design
Cohort
Follow-up
mean 27.8+/-8.8 months
Authors
Loading...
Elevated sCD40L was associated with higher vascular risk in nonvalvular AF; leaves open its incremental value for risk stratification.
Cohort (n=231)
Does elevated soluble CD40 ligand predict stroke or myocardial infarction in patients with nonvalvular atrial fibrillation?
Hazard Ratio: 4.63 (95% CI 1.92–11.2)
Absolute Event Rate: 25.2% vs 5.1%
p-value: p=<0.001
Elevated soluble CD40 ligand is a strong independent predictor of vascular events (stroke and MI) in patients with nonvalvular atrial fibrillation.
Ferro et al. (2007) conducted a cohort in Nonvalvular atrial fibrillation (n=231). High soluble CD40 ligand (sCD40L) levels (>4.76 ng/mL) vs. Low soluble CD40 ligand (sCD40L) levels (≤4.76 ng/mL) was evaluated on Vascular events (fatal and nonfatal stroke and myocardial infarction) (HR 4.63, 95% CI 1.92 to 11.20, p=<0.001). High plasma levels of soluble CD40 ligand significantly increased the risk of vascular events in patients with nonvalvular atrial fibrillation (HR 4.63; 95% CI 1.92-11.20; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: